BusinessEsperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 28, 2017, 8:30 PM UTC
BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:31 PM UTC
BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:30 PM UTC
BusinessEsperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare ConferenceBy Nasdaq OMXFeb 15, 2017, 9:30 PM UTC
BusinessEsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with HypercholesterolemiaBy Nasdaq OMXJan 25, 2017, 1:05 PM UTC
BusinessEsperion to Present at the 35th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 4, 2017, 10:00 PM UTC
